In vitro to in vivo extrapolation and high-content imaging for simultaneous characterization of chemically induced liver steatosis and markers of hepatotoxicity

[1]  L. Tolosa,et al.  Oxidative-stress and long-term hepatotoxicity: comparative study in Upcyte human hepatocytes and hepaRG cells , 2022, Archives of Toxicology.

[2]  Russell S. Thomas,et al.  Estimating Hepatotoxic Doses Using High-Content Imaging in Primary Hepatocytes. , 2021, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  A. Braeuning,et al.  More than additive effects on liver triglyceride accumulation by combinations of steatotic and non-steatotic pesticides in HepaRG cells , 2021, Archives of Toxicology.

[4]  C. Housset,et al.  In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal , 2020, Journal of clinical medicine.

[5]  S. Albaum,et al.  Transcript and protein marker patterns for the identification of steatotic compounds in human HepaRG cells. , 2020, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[6]  Y. Bahk,et al.  Metformin reduces saturated fatty acid-induced lipid accumulation and inflammatory response by restoration of autophagic flux in endothelial cells , 2020, Scientific Reports.

[7]  J. Kleinjans,et al.  Valproic acid promotes mitochondrial dysfunction in primary human hepatocytes in vitro; impact of C/EBPα-controlled gene expression , 2020, Archives of Toxicology.

[8]  B. Fromenty,et al.  Drug-induced hepatic steatosis in absence of severe mitochondrial dysfunction in HepaRG cells: proof of multiple mechanism-based toxicity , 2020, Cell Biology and Toxicology.

[9]  A. Zhang,et al.  The role of PSMB5 in sodium arsenite–induced oxidative stress in L-02 cells , 2020, Cell Stress and Chaperones.

[10]  A. Lampen,et al.  Comparison of long-term versus short-term effects of okadaic acid on the apoptotic status of human HepaRG cells. , 2020, Chemico-biological interactions.

[11]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[12]  Mehdi Koushki,et al.  Metformin reduces lipid accumulation in HepG2 cells via downregulation of miR-33b , 2019, Archives of physiology and biochemistry.

[13]  T. Petan,et al.  Lipid Droplets and the Management of Cellular Stress , 2019, The Yale journal of biology and medicine.

[14]  H. Raza,et al.  Augmentation of Glucotoxicity, Oxidative Stress, Apoptosis and Mitochondrial Dysfunction in HepG2 Cells by Palmitic Acid , 2019, Nutrients.

[15]  Hexin Yan,et al.  A DMSO-free hepatocyte maturation medium accelerates hepatic differentiation of HepaRG cells in vitro. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  Tianhe Zhao,et al.  Oxidative stress: One potential factor for arsenite-induced increase of N6-methyladenosine in human keratinocytes. , 2019, Environmental toxicology and pharmacology.

[17]  Bernd Wollscheid,et al.  Adverse Outcome Pathway-Driven Analysis of Liver Steatosis in Vitro: A Case Study with Cyproconazole. , 2018, Chemical research in toxicology.

[18]  Anne E Carpenter,et al.  CellProfiler 3.0: Next-generation image processing for biology , 2018, PLoS biology.

[19]  A. Federico,et al.  Role of Oxidative Stress in Pathophysiology of Nonalcoholic Fatty Liver Disease , 2018, Oxidative medicine and cellular longevity.

[20]  D. Lagadic-Gossmann,et al.  Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo , 2018, Scientific Reports.

[21]  T. Vanhaecke,et al.  Metabolomics profiling of steatosis progression in HepaRG® cells using sodium valproate. , 2018, Toxicology Letters.

[22]  A. Xu,et al.  Adipocyte Fatty Acid-Binding Protein Promotes Palmitate-Induced Mitochondrial Dysfunction and Apoptosis in Macrophages , 2018, Front. Immunol..

[23]  Joel N. Meyer,et al.  Mitochondrial Toxicity , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[24]  Jui-Hua Hsieh,et al.  An Intuitive Approach for Predicting Potential Human Health Risk with the Tox21 10k Library. , 2017, Environmental science & technology.

[25]  Elaine Cohen-Hubal,et al.  Editor’s Highlight: Mechanistic Toxicity Tests Based on an Adverse Outcome Pathway Network for Hepatic Steatosis , 2017, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  Nisha S Sipes,et al.  httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.

[27]  Thomas Hartung,et al.  Perspectives on In Vitro to In Vivo Extrapolations. , 2017, Applied in vitro toxicology.

[28]  M. Huang,et al.  Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis , 2017, Toxicology and applied pharmacology.

[29]  D. Merk,et al.  Therapeutic applications of the versatile fatty acid mimetic WY14643 , 2017, Expert opinion on therapeutic patents.

[30]  S. Orlow,et al.  Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review , 2017, American Journal of Clinical Dermatology.

[31]  Antony J. Williams,et al.  ToxCast Chemical Landscape: Paving the Road to 21st Century Toxicology. , 2016, Chemical research in toxicology.

[32]  M. T. Donato,et al.  Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. , 2016, Toxicology and applied pharmacology.

[33]  H. Trompeter,et al.  Modeling Nonalcoholic Fatty Liver Disease with Human Pluripotent Stem Cell-Derived Immature Hepatocyte-Like Cells Reveals Activation of PLIN2 and Confirms Regulatory Functions of Peroxisome Proliferator-Activated Receptor Alpha , 2016, Stem cells and development.

[34]  A. Okada,et al.  High content analysis assay for prediction of human hepatotoxicity in HepaRG and HepG2 cells. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.

[35]  Fabian P. Steinmetz,et al.  Using Molecular Initiating Events to Develop a Structural Alert Based Screening Workflow for Nuclear Receptor Ligands Associated with Hepatic Steatosis. , 2016, Chemical research in toxicology.

[36]  Fabian P. Steinmetz,et al.  The identification of nuclear receptors associated with hepatic steatosis to develop and extend adverse outcome pathways , 2016, Critical reviews in toxicology.

[37]  Mitchell R. McGill,et al.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen. , 2016, Toxicology and applied pharmacology.

[38]  G. Musso,et al.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies , 2016, Nature Reviews Drug Discovery.

[39]  Florent Baty,et al.  Dose-Response Analysis Using R , 2015, PLoS ONE.

[40]  G. Guo,et al.  Mechanistic review of drug-induced steatohepatitis. , 2015, Toxicology and applied pharmacology.

[41]  Melvin E. Andersen,et al.  Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.

[42]  Mathieu Vinken,et al.  Adverse Outcome Pathways and Drug-Induced Liver Injury Testing. , 2015, Chemical research in toxicology.

[43]  M. Maes,et al.  Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. , 2015, Progress in lipid research.

[44]  Barbara A Wetmore,et al.  Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment. , 2015, Toxicology.

[45]  E. Carrey,et al.  Orotic Acid, More Than Just an Intermediate of Pyrimidine de novo Synthesis. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[46]  P. Devarajan,et al.  Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[47]  P. Jennings,et al.  SEURAT-1 liver gold reference compounds: a mechanism-based review , 2014, Archives of Toxicology.

[48]  Timothy E H Allen,et al.  Defining molecular initiating events in the adverse outcome pathway framework for risk assessment. , 2014, Chemical research in toxicology.

[49]  Anne E Carpenter,et al.  Increasing the Content of High-Content Screening , 2014, Journal of biomolecular screening.

[50]  R. Weaver,et al.  PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. , 2014, Toxicology and applied pharmacology.

[51]  Danyan Xu,et al.  Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition , 2014, Drug Safety.

[52]  I. Pernicova,et al.  Metformin—mode of action and clinical implications for diabetes and cancer , 2014, Nature Reviews Endocrinology.

[53]  M. Averna,et al.  Lomitapide: a novel drug for homozygous familial hypercholesterolemia , 2014 .

[54]  Jorrit J Hornberg,et al.  A high content screening assay to predict human drug-induced liver injury during drug discovery. , 2013, Journal of pharmacological and toxicological methods.

[55]  Q. Saquib,et al.  Rotenone-induced oxidative stress and apoptosis in human liver HepG2 cells , 2013, Molecular and Cellular Biochemistry.

[56]  K.,et al.  Toxicant-associated Steatohepatitis , 2013, Toxicologic pathology.

[57]  D. Gaudet,et al.  Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study , 2013, The Lancet.

[58]  A. Guillouzo,et al.  Optimization of the HepaRG cell model for drug metabolism and toxicity studies. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[59]  J. Lipscomb,et al.  Putative Mechanisms of Environmental Chemical–Induced Steatosis , 2012, International journal of toxicology.

[60]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[61]  Tommy B Andersson,et al.  The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human , 2012, Expert opinion on drug metabolism & toxicology.

[62]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[63]  M. T. Donato,et al.  High-Content Imaging Technology for the Evaluation of Drug-Induced Steatosis Using a Multiparametric Cell-Based Assay , 2012, Journal of biomolecular screening.

[64]  G. Corso,et al.  Reference intervals for orotic acid in urine, plasma and dried blood spot using hydrophilic interaction liquid chromatography-tandem mass spectrometry. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[65]  F. Anania,et al.  GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy , 2011, PloS one.

[66]  A. Guillouzo,et al.  Induction of vesicular steatosis by amiodarone and tetracycline is associated with up‐regulation of lipogenic genes in heparg cells , 2011, Hepatology.

[67]  B. Fromenty,et al.  Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.

[68]  T. Vanden Hoek,et al.  Menadione triggers cell death through ROS-dependent mechanisms involving PARP activation without requiring apoptosis. , 2010, Free radical biology & medicine.

[69]  Robert J Kavlock,et al.  Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  Min Jae Lee,et al.  A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. , 2010, Gastroenterology.

[71]  Bas J Blaauboer,et al.  Biokinetic Modeling and in Vitro–in Vivo Extrapolations , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[72]  J. Castell,et al.  Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. , 2010, Chemico-biological interactions.

[73]  Youming Li,et al.  Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. , 2009, Journal of hepatology.

[74]  A. Guillouzo,et al.  Dose- and time-dependent effects of phenobarbital on gene expression profiling in human hepatoma HepaRG cells. , 2009, Toxicology and applied pharmacology.

[75]  Polina Golland,et al.  CellProfiler Analyst: data exploration and analysis software for complex image-based screens , 2008, BMC Bioinformatics.

[76]  Valérie Fessard,et al.  Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and Genotoxicity Studies , 2008, Drug Metabolism and Disposition.

[77]  I. Rusyn,et al.  WY-14,643 induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[78]  P. Ponikowski,et al.  A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. , 2007, Clinical science.

[79]  André Guillouzo,et al.  The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. , 2007, Chemico-biological interactions.

[80]  N. Mitro,et al.  T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR , 2007, FEBS letters.

[81]  José Vicente Castell,et al.  A human hepatocellular in vitro model to investigate steatosis. , 2007, Chemico-biological interactions.

[82]  André Guillouzo,et al.  EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS , 2006, Drug Metabolism and Disposition.

[83]  Polina Golland,et al.  Voronoi-Based Segmentation of Cells on Image Manifolds , 2005, CVBIA.

[84]  Christian Trépo,et al.  Origin and characterization of a human bipotent liver progenitor cell line. , 2004, Gastroenterology.

[85]  L. Siddoway.  Amiodarone: guidelines for use and monitoring. , 2003, American family physician.

[86]  B. Day,et al.  Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective , 2003, Nature Reviews Drug Discovery.

[87]  Robert V Farese,et al.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[88]  H. Ni,et al.  Etomoxir-induced oxidative stress in HepG2 cells detected by differential gene expression is confirmed biochemically. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[89]  A. Garber,et al.  Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. , 1997, The American journal of medicine.

[90]  M. Gaffey,et al.  Histopathologic changes associated with fialuridine hepatotoxicity. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[91]  J. Whang‐Peng,et al.  A pharmacokinetic study with the high-dose anticancer agent menadione in rabbits. , 1996, Biopharmaceutics & drug disposition.

[92]  H. Conjeevaram,et al.  Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. , 1995, The New England journal of medicine.

[93]  David Weininger,et al.  SMILES, a chemical language and information system. 1. Introduction to methodology and encoding rules , 1988, J. Chem. Inf. Comput. Sci..

[94]  J. L. Robinson,et al.  Species specificity in the metabolic consequences of orotic acid consumption. , 1980, The Journal of nutrition.

[95]  N. Chalasani,et al.  Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis , 2019, Drug Safety.

[96]  L. Henry,et al.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018, Nature Reviews Gastroenterology & Hepatology.

[97]  Elmar Heinzle,et al.  In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[98]  Menghang Xia,et al.  High-Throughput Screening Assays in Toxicology , 2016, Methods in Molecular Biology.

[99]  Jörg C Gerlach,et al.  HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. , 2011, Journal of pharmacological and toxicological methods.

[100]  P. Galtier,et al.  Orotic acid salts as sources of orotic acid and various minerals added for nutritional purposes to food supplements , 2009 .

[101]  J. Cha,et al.  THE LIVER X RECEPTOR AND HEPATIC LIPOGENESIS: THE CARBOHYDRATE-RESPONSE ELEMENT BINDING PROTEIN IS A TARGET GENE OF LXR , 2006 .

[102]  Bülent Sankur,et al.  Survey over image thresholding techniques and quantitative performance evaluation , 2004, J. Electronic Imaging.

[103]  Michigan.,et al.  Toxicological profile for dichloropropenes , 2008 .

[104]  F. Manning,et al.  Review of the Fialuridine (FIAU) Clinical Trials , 1995 .

[105]  B. Lowe.  Drug-induced toxicity , 1983 .

[106]  S. Schneider.  Valproic acid , 1980, The Western journal of medicine.

[107]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .